ERBB2 and triple-negative breast carcinoma: Simultaneously targeting cancer cells and the tumor microenvironment may be a good therapeutic strategy for currently incurable cancers, such as triple negative breast cancer: a heterogeneous group of breast cancer difficult to be treated by pre-existing chemotherapies for lacking estrogen receptor (ER), progesterone receptor (PR), and Her2/neu [26–29].